- Home
- QSI vs HURA Comparison
QSI vs HURA Comparison
Compare QSI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QSI | HURA |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | 145 | 22 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.6M | 160.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | QSI | HURA |
|---|---|---|
| Price | $0.82 | $2.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.00 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 4.9M | 731.4K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $618.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $0.41 |
| 52 Week High | $3.10 | $3.90 |
Technical Indicators
Market Signals| Indicator | QSI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 46.13 |
| Support Level | $0.69 | $2.14 |
| Resistance Level | $1.04 | $2.80 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 9.23 | 29.00 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.